Condition: Schizophrenia · Sponsor: MapLight Therapeutics
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).
This description comes directly from the study's public registry record.
Clinical Trials Contact Center · +1 650 839 4385 · ML-007C-MA-SCZ@maplightrx.com
Always discuss trial participation with your own doctor first.
| Clinical Site | Lemon Grove, California, United States | Recruiting |
| Clinical Site | Miami Lakes, Florida, United States | Recruiting |
| Clinical Site | Chicago, Illinois, United States | Recruiting |
| Clinical Site | Staten Island, New York, United States | Recruiting |
| Clinical Site | DeSoto, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07459647